New shot aims to tame genital herpes outbreaks

NCT ID NCT05298254

Completed Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested an experimental immunotherapy for herpes simplex virus (HSV) in 505 people. In the first part, healthy adults aged 18-40 received different vaccine-like formulations to check safety. In the second part, adults aged 18-60 with recurrent genital herpes got the treatment to see if it reduces outbreaks. The goal is to find a safe and effective way to control the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HSV-targeted immunotherapy (vaccine-like shots)
What this could lead to: If successful, this could lead to a treatment that reduces or prevents genital herpes outbreaks, helping people manage the condition better.
What could go wrong: This is an early-phase trial (phase 1/2), so it is primarily testing safety and immune response. The treatment may not reduce outbreaks, and side effects like pain, redness, or fever are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

genital herpes herpes simplex infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES SIMPLEX

Contacts and locations

Locations

GSK Investigational Site

Phoenix, Arizona, 85015, United States
GSK Investigational Site

Wichita, Kansas, 67207, United States
GSK Investigational Site

Kansas City, Missouri, 64114, United States
GSK Investigational Site

Rochester, New York, 14609, United States
GSK Investigational Site

Richmond, Virginia, 23219, United States
GSK Investigational Site

Seattle, Washington, 98105, United States
GSK Investigational Site

Darlinghurst, New South Wales, 2010, Australia
GSK Investigational Site

Sydney, New South Wales, 2010, Australia
GSK Investigational Site

Antwerp, 2000, Belgium
GSK Investigational Site

Brussels, 1000, Belgium
GSK Investigational Site

Edegem, 2650, Belgium
GSK Investigational Site

Ghent, 9000, Belgium
GSK Investigational Site

Montreal, Quebec, H2L 4E9, Canada
GSK Investigational Site

Tartu, 50106, Estonia
GSK Investigational Site

Berlin, 10117, Germany
GSK Investigational Site

Berlin, 10439, Germany
GSK Investigational Site

Bochum, 44787, Germany
GSK Investigational Site

Cologne, 50674, Germany
GSK Investigational Site

Frankfurt, 60596, Germany
GSK Investigational Site

Hamburg, 20146, Germany
GSK Investigational Site

Barcelona, 08001, Spain
GSK Investigational Site

Barcelona, 08015, Spain
GSK Investigational Site

Madrid, 28010, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Marbella, 29600, Spain
GSK Investigational Site

Brighton, BN2 1ES, United Kingdom
GSK Investigational Site

Liverpool, L7 8XP, United Kingdom
GSK Investigational Site

London, WC1E 6JB, United Kingdom
GSK Investigational Site

Southampton, SO14 0YG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.